Peyronie's disease was described by Francois de la Peyronie in 1743, a battlefield surgeon and Commander of the Medical Corps.
Areas covered: This narrative review discusses the safety profile of SGLT2is: initial concerns (cardiovascular safety, acute renal failure, hypoglycemia, urinary and genital infections, volume depletion, bladder cancer), further concerns (euglycemic ketoacidosis, bone fractures) and more recent concerns (lower limb amputation, Fournier’s gangrene).
Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cefotaxime sodium is indicated for the treatment of the following severe infections when known or thought very likely to be due to organisms that are susceptible to cefotaxime. ▪ Infections of the lower respiratory tract ▪ Infections of the kidneys and urinary tract ▪ Infections of the skin and soft tissue ▪ Genital infections caused by gonococci, particularly when penicillin has failed or is unsuitable ▪ Intra-abdominal infections (including Peritonitis) ▪ Lyme-borreliosis (especially stages II and III) ▪ Acute Meningitis in case of gram-negative microorganisms in combination with another suitable antibiotic ▪ Sepsis in case of gram-negative microorganism in combination with another suitable antibiotic ▪ Endocarditis in case of gram-negative microorganism in combination with another suitable antibiotic Peri-operative prophylaxis in surgical procedures such as colorectal, gastrointestinal, prostatic, urogenital and gynaecological surgery in patients who have a definite risk of post-operative infections. Cefotaxime should be used in combination with another antibiotic that can provide anaerobic cover in the treatment of intra-abdominal infections. Cefotaxime should be used in combination with an aminoglycoside in the treatment of infections caused by Pseudomonas. Protection is best insured by achieving adequate local tissue concentrations at the time contamination is likely to occur. Administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infection.